A doctor has issued an warning as to why Ozempic shouldn't be used for weight loss as it does one alarming thing to body.

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

Q2 2025 Results Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor Relations ...

Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 -- --With positive Phase 2b QUALITY study, Veru plans for end of Phase 2 ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

In recent years, blockbuster glucagon-like peptide 1 receptor agonist (GLP-1RA) therapies like Eli Lilly’s Zepbound ...

Obesity Program- enobosarm is ... meaningful benefit in the preservation of total lean body mass in all patients receiving enobosarm + semaglutide versus placebo + semaglutide at 16 weeks (71% ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

Home page Seeking Alpha - Power to Investors Create Free Account About Premium FREE Newsletters ...